Vident Investment Advisory, LLC Horizon Therapeutics Public LTD CO Transaction History

Vident Investment Advisory, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$107.32 - $113.5 $10.5 Million - $11.2 Million	-98,257 Reduced 95.31%	4,833 $527,000
Q4 2022 Feb 14, 2023	BUY	$62.39 - $113.8 $1.33 Million - $2.43 Million	21,355 Added 26.13%	103,090 $11.7 Million
Q3 2022 Nov 14, 2022	BUY	$58.92 - $84.67 $1.04 Million - $1.49 Million	17,593 Added 27.43%	81,735 $5.05 Million
Q2 2022 Aug 15, 2022	BUY	$79.4 - $116.36 $778,358 - $1.14 Million	9,803 Added 18.04%	64,142 $5.12 Million
Q1 2022 May 16, 2022	BUY	$86.42 - $109.81 $1.28 Million - $1.63 Million	14,845 Added 37.59%	54,339 $5.72 Million
Q4 2021 Feb 14, 2022	BUY	$98.56 - $119.91 $610,677 - $742,962	6,196 Added 18.61%	39,494 $4.26 Million
Q3 2021 Nov 12, 2021	SELL	$91.91 - $110.37 $176,191 - $211,579	-1,917 Reduced 5.44%	33,298 $3.65 Million
Q2 2021 Aug 13, 2021	BUY	$86.24 - $95.92 $2.36 Million - $2.62 Million	27,356 Added 348.08%	35,215 $3.3 Million
Q1 2021 May 14, 2021	BUY	$71.83 - $95.48 $28,732 - $38,192	400 Added 5.36%	7,859 $724,000
Q4 2020 Feb 08, 2021	SELL	$67.0 - $84.39 $121,538 - $153,083	-1,814 Reduced 19.56%	7,459 $545,000
Q3 2020 Nov 12, 2020	BUY	$55.23 - $79.93 $512,147 - $741,190	9,273 New	9,273 $720,000

2.07M

20K

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.